Skip to main content
Top
Published in: Annals of Hematology 7/2013

Open Access 01-07-2013 | Original Article

The incidence of myelodysplastic syndromes in Western Greece is increasing

Authors: Christina Avgerinou, Yannis Alamanos, Panagiotis Zikos, Polyxeni Lampropoulou, Maria Melachrinou, Vassiliki Labropoulou, Ioannis Tavernarakis, Anthi Aktypi, Panagiotis Kaiafas, Christos Raptis, Alexandra Kouraklis, Marina Karakantza, Argiris Symeonidis

Published in: Annals of Hematology | Issue 7/2013

Login to get access

Abstract

Descriptive epidemiology of the myelodysplastic syndromes (MDS) is always interesting and may reveal time-dependent and geographical variations, as well as occupational exposure. Epidemiological data in Greece are not available by now. We have collected and analyzed medical records of all patients with a documented diagnosis of MDS, performed by an expert hematologist and/or hematopathologist, in the geographical area of Western Greece, during the 20-year period, defined between 1990 and 2009. We have then calculated and described demographic and clinical features of the diagnosed MDS patient population, and assessed the incidence and prevalence rates of MDS in Western Greece, during the above-mentioned period. A total of 855 patients with newly diagnosed MDS have been identified. Refractory anemia was the most common subtype in both FAB and WHO classification systems and in both genders. Del-5q and RARS were more commonly encountered among females, and the dysplastic subtype of chronic myelomonocytic leukemia among males. Trisomy 8 was the most common single cytogenetic abnormality. The crude mean annual incidence rate of MDS was 6.0 per 100,000 inhabitants aged ≥15 years old (all subtypes according to FAB), and it was 4.8 per 100,000 when CMML and RAEB-T were excluded. Crude incidence rate was higher in rural than in urban areas, but this finding was not confirmed after age standardization. Age-standardized mean annual incidence rate in men was 7.9/100,000 and in women 3.4/100,000. A continuously increasing incidence rate of MDS has been observed throughout the study period.
Literature
1.
go back to reference Bennett JM (2002) The myelodysplastic syndromes. Pathobiology and clinical management. Marcel Dekker Inc, New York, p 15, Chapter 2 Bennett JM (2002) The myelodysplastic syndromes. Pathobiology and clinical management. Marcel Dekker Inc, New York, p 15, Chapter 2
2.
go back to reference Lipschitz DA, Udupa KB, Milton KY, Thompson CO (1984) Effect of age on hematopoiesis in man. Blood 63:502–509PubMed Lipschitz DA, Udupa KB, Milton KY, Thompson CO (1984) Effect of age on hematopoiesis in man. Blood 63:502–509PubMed
3.
go back to reference Germing U, Neukirchen J, Haas R (2008) The epidemiology of myelodysplastic syndromes. Clin Leukemia 2(Feb):34–38CrossRef Germing U, Neukirchen J, Haas R (2008) The epidemiology of myelodysplastic syndromes. Clin Leukemia 2(Feb):34–38CrossRef
4.
go back to reference Strom SS, Velez-Bravo V, Estey EH (2008) Epidemiology of myelodysplastic syndromes. Semin Hematol 45:8–13PubMedCrossRef Strom SS, Velez-Bravo V, Estey EH (2008) Epidemiology of myelodysplastic syndromes. Semin Hematol 45:8–13PubMedCrossRef
5.
go back to reference Shimizu H, Matsushita Y, Aoki K, Nomura T, Yoshida Y, Mizoguchi H (1995) Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol 61:17–22PubMedCrossRef Shimizu H, Matsushita Y, Aoki K, Nomura T, Yoshida Y, Mizoguchi H (1995) Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol 61:17–22PubMedCrossRef
6.
go back to reference Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87:743–745PubMedCrossRef Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, Oscier DG (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87:743–745PubMedCrossRef
7.
go back to reference Breslow NE, Day NE (1987) Rates and rate standardisation. In: Heseltine E, technical editor for IARC. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. Lyon: IARC Scientific Publications 48–79 Breslow NE, Day NE (1987) Rates and rate standardisation. In: Heseltine E, technical editor for IARC. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. Lyon: IARC Scientific Publications 48–79
8.
go back to reference Bouyer J, Hemon D, Cordier S, Derrienic F, Stucker I, Stengel B, Clavel J (1993) Standardisation des mesures de risque et d’association. In: Epidémiologie. Principes et méthodes quantitatives. Paris: Les editions INSERM 209–226 Bouyer J, Hemon D, Cordier S, Derrienic F, Stucker I, Stengel B, Clavel J (1993) Standardisation des mesures de risque et d’association. In: Epidémiologie. Principes et méthodes quantitatives. Paris: Les editions INSERM 209–226
9.
go back to reference Maynadié M, Verret C, Moskovtchenko P, Mugneret F, Petrell T, Caillot D, Carli PM (1996) Epidemiological characteristics of myelodysplastic syndromes in a well-defined French population. Br J Cancer 74:288–290PubMedCrossRef Maynadié M, Verret C, Moskovtchenko P, Mugneret F, Petrell T, Caillot D, Carli PM (1996) Epidemiological characteristics of myelodysplastic syndromes in a well-defined French population. Br J Cancer 74:288–290PubMedCrossRef
10.
go back to reference Phekoo KJ, Richards MA, Moller H, Schey SA (2006) The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East England. Haematologica 91:1400–1404PubMed Phekoo KJ, Richards MA, Moller H, Schey SA (2006) The incidence and outcome of myeloid malignancies in 2,112 adult patients in South East England. Haematologica 91:1400–1404PubMed
11.
go back to reference Aul C, Gattermann N, Schneider W (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:358–367PubMedCrossRef Aul C, Gattermann N, Schneider W (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 82:358–367PubMedCrossRef
12.
go back to reference Bauduer F, Ducout L, Dastugue N, Capdupuy C, Renoux M (1998) Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leuk Res 22:205–208PubMedCrossRef Bauduer F, Ducout L, Dastugue N, Capdupuy C, Renoux M (1998) Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leuk Res 22:205–208PubMedCrossRef
13.
go back to reference Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U (2011) Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS registry. Leuk Res 35:1591–1596PubMedCrossRef Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R, Germing U (2011) Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS registry. Leuk Res 35:1591–1596PubMedCrossRef
14.
go back to reference Iglesias Gallego M, Sastre Moral JL, Gayoso Diz P, Garcia Costa A, Ros Forteza S, Mayan Santos JM (2003) Incidence and characteristics of myelodysplastic syndromes in Ourense (Spain) between 1994–1998. Haematologica/Journal of Hematology 88:1197–1199 Iglesias Gallego M, Sastre Moral JL, Gayoso Diz P, Garcia Costa A, Ros Forteza S, Mayan Santos JM (2003) Incidence and characteristics of myelodysplastic syndromes in Ourense (Spain) between 1994–1998. Haematologica/Journal of Hematology 88:1197–1199
15.
go back to reference Van den Berghe H, Vermaelen K, Merucci C, Barbieri D, Tricot G (1985) The 5q-anomaly. Cancer Genet Cytogenet 17:189–225PubMedCrossRef Van den Berghe H, Vermaelen K, Merucci C, Barbieri D, Tricot G (1985) The 5q-anomaly. Cancer Genet Cytogenet 17:189–225PubMedCrossRef
16.
go back to reference Ribera JM, Cervantes F, Rozman C (1987) A multivariate analysis of prognostic factors in chronic myelomonocytic leukemia according to the FAB criteria. Br J Haematol 65:307–311PubMedCrossRef Ribera JM, Cervantes F, Rozman C (1987) A multivariate analysis of prognostic factors in chronic myelomonocytic leukemia according to the FAB criteria. Br J Haematol 65:307–311PubMedCrossRef
17.
go back to reference Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed Greenberg P, Cox C, LeBeau MM et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed
18.
go back to reference Cartwright RA (1992) Incidence and epidemiology of the myelodysplastic syndromes. In: Mufti GJ, Galton DAG (eds) The myelodysplastic syndromes. Churchill Livingstone, Edinburgh, pp 23–31 Cartwright RA (1992) Incidence and epidemiology of the myelodysplastic syndromes. In: Mufti GJ, Galton DAG (eds) The myelodysplastic syndromes. Churchill Livingstone, Edinburgh, pp 23–31
19.
go back to reference Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L (1995) Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 54:153–156PubMedCrossRef Radlund A, Thiede T, Hansen S, Carlsson M, Engquist L (1995) Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol 54:153–156PubMedCrossRef
20.
go back to reference Phillips MJ, Cull GM, Ewings M (1994) Establishing the incidence of myelodysplasia syndrome. Br J Haematol 88:896–897PubMedCrossRef Phillips MJ, Cull GM, Ewings M (1994) Establishing the incidence of myelodysplasia syndrome. Br J Haematol 88:896–897PubMedCrossRef
21.
go back to reference Gologan R (2010) Demo-geographical data of myelodysplastic syndrome based on a large sample of patients from a Romanian Hematological Center. J BUON 15:547–555PubMed Gologan R (2010) Demo-geographical data of myelodysplastic syndrome based on a large sample of patients from a Romanian Hematological Center. J BUON 15:547–555PubMed
22.
go back to reference Ma X, Does M, Raza A, Mayne ST (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109:1536–1542PubMedCrossRef Ma X, Does M, Raza A, Mayne ST (2007) Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109:1536–1542PubMedCrossRef
23.
go back to reference Rollison DE, Howlader N, Smith MT, Strom SS, Merrit WD, Ries LA, Edward BK, List AF (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112:45–52PubMedCrossRef Rollison DE, Howlader N, Smith MT, Strom SS, Merrit WD, Ries LA, Edward BK, List AF (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 112:45–52PubMedCrossRef
24.
go back to reference Cogle CR, Craig BM, Rollison DE, List AF (2011) Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117:7121–7125PubMedCrossRef Cogle CR, Craig BM, Rollison DE, List AF (2011) Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117:7121–7125PubMedCrossRef
25.
go back to reference De Roos AJ, Deeg HJ, Onstad L, Kopecky KJ, Aiello EJ, Yong M, Fryzek J, Davis S (2010) Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state 2005–2006. Am J Hematol 85:765–770PubMedCrossRef De Roos AJ, Deeg HJ, Onstad L, Kopecky KJ, Aiello EJ, Yong M, Fryzek J, Davis S (2010) Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state 2005–2006. Am J Hematol 85:765–770PubMedCrossRef
26.
go back to reference Shimizu H, Matsushita Y, Aoki K, Nomura T, Yoshida Y, Mizoguchi H (1995) Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol 61:17–22PubMedCrossRef Shimizu H, Matsushita Y, Aoki K, Nomura T, Yoshida Y, Mizoguchi H (1995) Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol 61:17–22PubMedCrossRef
27.
go back to reference McNally RJQ, Roman E, Cartwright RA (1999) Leukemias and lymphomas: time trends in the UK, 1984–93. Cancer Causes Control 10:35–42PubMedCrossRef McNally RJQ, Roman E, Cartwright RA (1999) Leukemias and lymphomas: time trends in the UK, 1984–93. Cancer Causes Control 10:35–42PubMedCrossRef
28.
go back to reference Aul C, Giagounidis A, Germing U (2001) Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 73:405–410PubMedCrossRef Aul C, Giagounidis A, Germing U (2001) Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 73:405–410PubMedCrossRef
29.
go back to reference Germing U, Strupp C, Kundgen A, Bowen D, Aul C, Haas R, Gattermann N (2004) No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 89:905–910PubMed Germing U, Strupp C, Kundgen A, Bowen D, Aul C, Haas R, Gattermann N (2004) No increase in age-specific incidence of myelodysplastic syndromes. Haematologica 89:905–910PubMed
Metadata
Title
The incidence of myelodysplastic syndromes in Western Greece is increasing
Authors
Christina Avgerinou
Yannis Alamanos
Panagiotis Zikos
Polyxeni Lampropoulou
Maria Melachrinou
Vassiliki Labropoulou
Ioannis Tavernarakis
Anthi Aktypi
Panagiotis Kaiafas
Christos Raptis
Alexandra Kouraklis
Marina Karakantza
Argiris Symeonidis
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 7/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-013-1712-6

Other articles of this Issue 7/2013

Annals of Hematology 7/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine